Meta-analysis of 11 studies (477 patients) of belumosudil in chronic graft-versus-host disease: pooled 12-month overall response was 73%, 58% reduced corticosteroids and 12-month survival was 87%; serious adverse events occurred in 38.9%.
Meta-analysisn = 477
Gadelmawla et al. Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis